Literature DB >> 23790799

Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.

Hagop M Kantarjian1, Susan O'Brien, Jorge Cortes.   

Abstract

Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CML; Homoharringtonine (HHT); Omacetaxine mepesuccinate; Treatment

Mesh：

Substances：

Year:  2013        PMID： 23790799      PMCID： PMC3775965          DOI： 10.1016/j.clml.2013.03.017

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


  30 in total

1.  Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.

Authors:  H M Kantarjian; M J Keating; R S Walters; C A Koller; K B McCredie; E J Freireich
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

2.  [A preliminary therapeutic analysis of 82 cases of chronic granulocytic leukemia treated with harringtonine].

Authors:  Z Y Zhang; C H Hou; Y F Zhu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1986-03

3.  Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.

Authors:  S O'Brien; H Kantarjian; C Koller; E Feldman; M Beran; M Andreeff; S Giralt; B Cheson; M Keating; E Freireich; M B Rios; M Talpaz
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

4.  Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.

Authors:  David Marin; Jaspal S Kaeda; Catharina Andreasson; Sue M Saunders; Marco Bua; Eduardo Olavarria; John M Goldman; Jane F Apperley
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

5.  Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Zeev Estrov; Francis Giles; Anthony Murgo; Nakia Ladie; Srdan Verstovsek; Jorge Cortes
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

6.  Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study.

Authors:  J A Stewart; P A Cassileth; J M Bennett; M J O'Connell
Journal:  Am J Clin Oncol       Date:  1988-12       Impact factor: 2.339

7.  Small-dose Harringtonine induces complete remission in patients with acute promyelocytic leukemia.

Authors:  J S Ye; X H Wang; G H Feng; G R Liang; Z P Liu
Journal:  Leukemia       Date:  1988-07       Impact factor: 11.528

8.  Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.

Authors:  S O'Brien; H Kantarjian; M Keating; M Beran; C Koller; L E Robertson; J Hester; M B Rios; M Andreeff; M Talpaz
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

9.  Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.

Authors:  E J Feldman; K P Seiter; T Ahmed; P Baskind; Z A Arlin
Journal:  Leukemia       Date:  1996-01       Impact factor: 11.528

10.  Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.

Authors:  E Feldman; Z Arlin; T Ahmed; A Mittelman; C Puccio; H Chun; P Cook; P Baskind
Journal:  Leukemia       Date:  1992-11       Impact factor: 11.528
View more
  32 in total

1.  Stereoselective Dynamic Cyclization of Allylic Azides: Synthesis of Tetralins, Chromanes, and Tetrahydroquinolines.

Authors:  Matthew R Porter; Rami M Shaker; Cristian Calcanas; Joseph J Topczewski
Journal:  J Am Chem Soc       Date:  2018-01-10       Impact factor: 15.419

2.  Liposomal co-delivery of omacetaxine mepesuccinate and doxorubicin for synergistic potentiation of antitumor activity.

Authors:  Gayong Shim; Sangbin Lee; Junhyeok Choi; Soondong Lee; Chan-Wha Kim; Yu-Kyoung Oh
Journal:  Pharm Res       Date:  2014-02-22       Impact factor: 4.200

3.  Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel.

Authors:  Arren Z Washington; Subhasish Tapadar; Alex George; Adegboyega K Oyelere
Journal:  Bioorg Med Chem       Date:  2015-05-06       Impact factor: 3.641

4.  Curcumin in Combination With Omacetaxine Suppress Lymphoma Cell Growth, Migration, Invasion, and Angiogenesis via Inhibition of VEGF/Akt Signaling Pathway.

Authors:  Yu Zhang; Jingjing Xiang; Ni Zhu; Hangping Ge; Xianfu Sheng; Shu Deng; Junfa Chen; Lihong Yu; Yan Zhou; Jianping Shen
Journal:  Front Oncol       Date:  2021-08-11       Impact factor: 6.244

Review 5.  How Should the Worldwide Knowledge of Traditional Cancer Healing Be Integrated with Herbs and Mushrooms into Modern Molecular Pharmacology?

Authors:  Yulia Kirdeeva; Olga Fedorova; Alexandra Daks; Nikolai Barlev; Oleg Shuvalov
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-14

6.  Homoharringtonine production by endophytic fungus isolated from Cephalotaxus hainanensis Li.

Authors:  Xiaoping Hu; Wu Li; Mu Yuan; Congfa Li; Sixin Liu; Chunjie Jiang; Yanchun Wu; Kun Cai; Yan Liu
Journal:  World J Microbiol Biotechnol       Date:  2016-06-04       Impact factor: 3.312

7.  Discovery of Surfactins as Inhibitors of MicroRNA Processing Using Cat-ELCCA.

Authors:  Andrew W Robertson; Jorge Sandoval; Osama G Mohamed; Yihao Zhuang; Erin E Gallagher; Jennifer Schmidt; Lisa Caratelli; Arya Menon; Pamela J Schultz; Rachel M Torrez; Catherine L Hay; Bailey A Bell; Paul A Price; Amanda L Garner; Ashootosh Tripathi
Journal:  ACS Med Chem Lett       Date:  2021-04-02       Impact factor: 4.632

Review 8.  Cephalotaxus Alkaloids.

Authors:  Joëlle Pérard-Viret; Laith Quteishat; Rana Alsalim; Jacques Royer; Françoise Dumas
Journal:  Alkaloids Chem Biol       Date:  2017-08-16

9.  Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis.

Authors:  Stephan Philipp; Justyna Sosna; Johannes Plenge; Holger Kalthoff; Dieter Adam
Journal:  Cell Commun Signal       Date:  2015-04-29       Impact factor: 5.712

10.  High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.

Authors:  Nicholas C Wolff; Andrea Pavía-Jiménez; Vanina T Tcheuyap; Shane Alexander; Mridula Vishwanath; Alana Christie; Xian-Jin Xie; Noelle S Williams; Payal Kapur; Bruce Posner; Renée M McKay; James Brugarolas
Journal:  Oncotarget       Date:  2015-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.